Paul Edward Kelly, Director at RELMADA THERAPEUTICS, INC. (RLMD), bought 5,000 shares at $1.21 ($6K) on 2018-12-11, disclosed to the SEC on 2018-12-11.
Open-market purchase of $6k RLMD by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |
| RLMD | BUY | 2024-09-11 | $65K | — | Filing → |
| RLMD | SELL | 2022-04-05 | $300K | — | Filing → |
| RLMD | SELL | 2021-03-11 | $357K | — | Filing → |